GT Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-13.16	-7.6	-20.88	-58.01	-28.3	Upgrade
Other Amortization	-	-	-	-	0.32	Upgrade
Asset Writedown & Restructuring Costs	-	-	-	-	0.06	Upgrade
Loss (Gain) From Sale of Investments	-	-0.05	0.03	0.03	-	Upgrade
Stock-Based Compensation	0.23	2.2	7.65	33.93	0.27	Upgrade
Other Operating Activities	-0.75	-5.23	-0.02	0.51	17.98	Upgrade
Change in Accounts Payable	0.94	1.96	-2.03	7.08	-0.84	Upgrade
Change in Other Net Operating Assets	-0.16	-0.14	0.04	0.86	3.24	Upgrade
Operating Cash Flow	-12.9	-8.85	-15.22	-15.61	-7.26	Upgrade
Investment in Securities	12.89	-2.01	12.15	-23.04	-	Upgrade
Investing Cash Flow	12.89	-2.01	12.15	-23.04	-	Upgrade
Short-Term Debt Issued	-	-	-	1.21	12.53	Upgrade
Total Debt Issued	-	-	-	1.21	12.53	Upgrade
Net Debt Issued (Repaid)	-	-	-	1.21	12.53	Upgrade
Issuance of Common Stock	2.98	6.27	-	41.11	-	Upgrade
Repurchase of Common Stock	-	-	-0.22	-	-	Upgrade
Financing Cash Flow	2.98	6.27	-0.22	42.32	12.53	Upgrade
Net Cash Flow	2.97	-4.59	-3.3	3.67	5.27	Upgrade
Free Cash Flow	-12.9	-8.85	-15.22	-15.61	-7.26	Upgrade
Free Cash Flow Per Share	-6.80	-6.57	-14.32	-16.63	-49.68	Upgrade
Cash Interest Paid	-	0.21	-	-	-	Upgrade
Levered Free Cash Flow	-9.62	-4.68	-10.91	-0.82	-3.42	Upgrade
Unlevered Free Cash Flow	-9.62	-4.55	-10.9	-0.38	-1.66	Upgrade
Change in Net Working Capital	0.87	-1.72	5.26	-1.64	-2.29	Upgrade

Updated Feb 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q